Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000169295 | SCV000220614 | likely pathogenic | Infantile hypophosphatasia | 2014-08-21 | criteria provided, single submitter | literature only | |
| Labcorp Genetics |
RCV001204937 | SCV001376168 | pathogenic | not provided | 2023-06-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects ALPL function (PMID: 19500388). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALPL protein function. ClinVar contains an entry for this variant (Variation ID: 188928). This missense change has been observed in individual(s) with clinical features of hypophosphatasia (PMID: 19500388, 22397652; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs781264043, gnomAD 0.0009%). This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 72 of the ALPL protein (p.Ile72Thr). |
| Baylor Genetics | RCV003474904 | SCV004193864 | likely pathogenic | Adult hypophosphatasia | 2022-02-14 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV005008090 | SCV005640544 | likely pathogenic | Adult hypophosphatasia; Childhood hypophosphatasia; Infantile hypophosphatasia | 2024-03-21 | criteria provided, single submitter | clinical testing | |
| Prevention |
RCV004552944 | SCV004765176 | pathogenic | ALPL-related disorder | 2023-12-18 | no assertion criteria provided | clinical testing | The ALPL c.215T>C variant is predicted to result in the amino acid substitution p.Ile72Thr. This variant in the heterozygous state was reported in one patient affected with odontohypophosphatasia (Fauvert et al. 2009. PubMed ID: 19500388), and in the compound heterozygous state, this variant was found in a patient affected with perinatal hypophosphatasia (Whyte et al. 2012. PubMed ID: 22397652). In addition, a different variant affecting the same amino acid (p.Ile72Val) was reported in one individual with hypophosphatasia (Glotov et al. 2022. PubMed ID: 36361766). This variant is reported in 0.00089% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-21887623-T-C). At PreventionGenetics, we have observed this variant in several unrelated individuals tested for ALPL (internal data). In summary, this variant is interpreted as pathogenic. |